Medicilon Assists Zhigen Pharmaceutical's new antidepressant drug ZG-001 to get approval for clinical trials

 Recently, the Class 1 innovative drug ZG-001 developed by Shanghai Zhigen Pharmaceutical Technology Co., Ltd. (Zhigen Pharmaceutical) has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (NMPA).  ZG-001 is intended for the treatment of depressive disorders in adults, including major depressive disorder associated with suicidal ideation or behavior (MDSI) or treatment-resistant depression (TRD) or major depressive disorder (MDD).

Shanghai Medicilon Inc. (Medicilon), as a partner of Zhigen Pharmaceutical, provided ZG-001 with one-stop R&D services such as pharmaceutical research (including raw materials and preparations), preclinical research (including pharmacokinetics, safety evaluation), and IND filing application, which successfully obtained the clinical approval and accelerated the R&D process.

One-stop preclinical R&D service platform
Medicilon empowers new drug R&D to be faster and cheaper

For new drug research and development, speed and quality are key factors that determine success or failure, and they are also industry challenges that have attracted much attention.  Medicilon's "One-stop biopharmaceutical preclinical R&D service platform" can shorten the R&D cycle and improve the quality of new drug R&D.

Having been deeply involved in the field of preclinical R&D for nearly 20 years, Medicilon continues to innovate R&D technology and expand upstream and downstream service areas of the industrial chain based on the needs of new drug R&D.  Medicilon has successfully created a comprehensive and integrated pre-clinical CRO service model, which can not only seamlessly connect traditional R&D links in series, but also integrate into a parallel R&D model.  Relying on the service advantages of rigorous planning, efficient collaboration, and orderly advancement, Medicilon can empower the R&D of new drugs faster, better, and more cost-effective.

Medicilon congratulates Zhigen Pharmaceutical on its clinical approval of ZG-001 and looks forward to ZG-001 achieving positive results in clinical trials and bringing about revolutionary changes in clinical drug selection for depression as soon as possible.  Medicilon's one-stop biopharmaceutical R&D service platform will continue to innovate and iterate to improve and accelerate global drug R&D.

About Zhigen Pharmaceutical
Zhigen Pharmaceutical is a company mainly engaged in the research and development of new drugs, committed to the research and development of innovative small molecule drugs, focusing on unmet clinical needs in severe mental illness, autoimmune diseases, tumors and other fields, as well as develop First in Class or Best in Class chemical innovative drugs.  Zhigen Pharmaceutical's main innovative drugs under development have obvious advantages in terms of efficacy, metabolism and safety.

About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 385 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.